Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference
Galectin Therapeutics (NASDAQ: GALT), a leader in developing galectin protein-targeting therapeutics, has announced its participation in the upcoming H.C. Wainwright MASH Investor Conference on October 7, 2024. Joel Lewis, CEO, and Dr. Khurram Jamil, CMO, will be attending the event.
Dr. Jamil is scheduled to present at 10:00 AM ET on October 7, 2024, providing the latest updates on the company's clinical programs and pipeline advancements. Interested parties can access the presentation webcast through a provided link or via the Events & Presentation page in the investors section of the Galectin Therapeutics website.
This conference participation underscores Galectin Therapeutics' commitment to keeping investors informed about their progress in developing innovative therapeutics targeting galectin proteins.
Galectin Therapeutics (NASDAQ: GALT), un leader nello sviluppo di terapeutiche mirate alle proteine galectine, ha annunciato la sua partecipazione al prossimo H.C. Wainwright MASH Investor Conference il 7 ottobre 2024. Joel Lewis, CEO, e Dr. Khurram Jamil, CMO, parteciperanno all'evento.
Il Dr. Jamil presenterà alle 10:00 AM ET del 7 ottobre 2024, fornendo gli ultimi aggiornamenti sui programmi clinici e i progressi della pipeline dell'azienda. Le parti interessate possono accedere alla presentazione in webcast tramite un link fornito o tramite la pagina Eventi & Presentazioni nella sezione investor del sito web di Galectin Therapeutics.
Questa partecipazione alla conferenza sottolinea l'impegno di Galectin Therapeutics nel mantenere gli investitori informati sui loro progressi nello sviluppo di terapie innovative mirate alle proteine galectine.
Galectin Therapeutics (NASDAQ: GALT), un líder en el desarrollo de terapéuticas que apuntan a las proteínas galectinas, ha anunciado su participación en la próxima H.C. Wainwright MASH Investor Conference el 7 de octubre de 2024. Joel Lewis, CEO, y Dr. Khurram Jamil, CMO, asistirán al evento.
El Dr. Jamil está programado para presentar a las 10:00 AM ET del 7 de octubre de 2024, brindando las últimas actualizaciones sobre los programas clínicos y los avances en la pipeline de la compañía. Las partes interesadas pueden acceder a la presentación a través de un enlace proporcionado o mediante la página de Eventos y Presentaciones en la sección de inversores del sito web de Galectin Therapeutics.
La participación en esta conferencia resalta el compromiso de Galectin Therapeutics de mantener a los inversores informados sobre su progreso en el desarrollo de terapias innovadoras que apuntan a las proteínas galectinas.
갈렉틴 치료제 (NASDAQ: GALT)는 갈렉틴 단백질 표적 치료제 개발의 선두주자로서 2024년 10월 7일에 열리는 H.C. Wainwright MASH 투자자 회의에 참여할 것이라고 발표했습니다. Joel Lewis CEO와 Dr. Khurram Jamil CMO가 이 행사에 참석할 예정입니다.
Jamil 박사는 2024년 10월 7일 오전 10:00 ET에 발표할 예정이며, 회사의 임상 프로그램과 파이프라인 발전에 대한 최신 정보를 제공합니다. 관심 있는 관람객들은 제공된 링크를 통해 웹캐스트를 시청하거나 갈렉틴 치료제 웹사이트의 투자자 섹션에 있는 이벤트 및 발표 페이지를 통해 발표에 접근할 수 있습니다.
이번 회의 참여는 갈렉틴 치료제가 갈렉틴 단백질을 목표로 하는 혁신적인 치료제 개발에 대한 진행 상황을 투자자들에게 알리는 데 전념하고 있음을 강조합니다.
Galectin Therapeutics (NASDAQ: GALT), un leader dans le développement de thérapeutiques ciblant les protéines galectines, a annoncé sa participation à la prochaine H.C. Wainwright MASH Investor Conference qui se tiendra le 7 octobre 2024. Joel Lewis, PDG, et Dr. Khurram Jamil, CMO, assisteront à l'événement.
Le Dr. Jamil est prévu pour présenter à 10h00 ET le 7 octobre 2024, fournissant les dernières mises à jour sur les programmes cliniques et les avancées de la pipeline de l'entreprise. Les parties intéressées peuvent accéder à la webdiffusion de la présentation via un lien fourni ou via la page Événements & Présentations dans la section investisseurs du site web de Galectin Therapeutics.
Cette participation à la conférence souligne l'engagement de Galectin Therapeutics à tenir les investisseurs informés de leurs progrès dans le développement de thérapies innovantes ciblant les protéines galectines.
Galectin Therapeutics (NASDAQ: GALT), ein führendes Unternehmen in der Entwicklung von therapeutischen Ansätzen, die auf Galectin-Proteine abzielen, hat seine Teilnahme an der bevorstehenden H.C. Wainwright MASH Investor Conference am 7. Oktober 2024 angekündigt. Joel Lewis, CEO, und Dr. Khurram Jamil, CMO, werden an der Veranstaltung teilnehmen.
Dr. Jamil ist geplant, am 7. Oktober 2024 um 10:00 AM ET zu präsentieren und die neuesten Informationen über die klinischen Programme und die Fortschritte in der Pipeline des Unternehmens zu geben. Interessierte Parteien können über einen bereitgestellten Link auf das Präsentations-Webcast zugreifen oder über die Seite Veranstaltungen & Präsentationen im Investorenbereich der Webseite von Galectin Therapeutics darauf zugreifen.
Die Teilnahme an dieser Konferenz unterstreicht das Engagement von Galectin Therapeutics, Investoren über ihre Fortschritte bei der Entwicklung innovativer therapeutischer Ansätze, die auf Galectin-Proteine abzielen, zu informieren.
- None.
- None.
NORCROSS, Ga., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer and Khurram Jamil, M.D., Chief Medical Officer, will be attending the H.C. Wainwright MASH Investor Conference being held October 7, 2024.
Dr. Jamil will be sharing the latest updates on clinical programs and pipeline advancement on October 7, 2024 at 10:00 AM ET. The webcast of the presentation can be accessed here or through the Company’s website on the Events & Presentation page of the investors section.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.
Company Contact:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com
Investors Relations Contacts:
Kevin Gardner
kgardner@lifesciadvisors.com
Chris Calabrese
ccalabrese@lifesciadvisors.com
Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor belapectin.
FAQ
When is Galectin Therapeutics (GALT) presenting at the H.C. Wainwright MASH Conference?
Who will be representing Galectin Therapeutics (GALT) at the H.C. Wainwright MASH Conference?
What will Galectin Therapeutics (GALT) discuss at the H.C. Wainwright MASH Conference?
How can investors access Galectin Therapeutics' (GALT) presentation at the H.C. Wainwright MASH Conference?
